Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors in 75% of patients with recurrent or persistent estrogen receptor-positive, or ER-positive, endometrial cancer.
“For patients with ER-positive endometrial cancer, hormonal/endocrine therapy is used as an alternative option after progression through chemotherapy and immunotherapy or as an alternative, less toxic option for those with more indolent or minimally symptomatic disease,” Panagiotis A. Konstantinopoulos, MD, PhD, director of gynecologic oncology translational